Cook Medical Brings Hemospray™ to U.S. Physicians to Treat Gastrointestinal Bleeds

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

The FDA has granted Cook Medical approval to market Hemospray in the United States. An endoscopic hemostat, Hemospray achieves hemostasis with a proprietary inorganic powder.

Bleeding in the gastrointestinal tract is a leading cause of morbidity and is associated with an estimated 20,000 deaths per year in the United States alone.1 Since 2011, Cook Medical’s Hemospray has been used to treat bleeding in the GI tract, with thousands of patients treated throughout Europe, Canada and other countries around the globe.

“We are extremely pleased to receive this approval to market from FDA,” said Barry Slowey, president of Cook Winston-Salem and vice president of Cook Medical’s Endoscopy specialty. “We have worked diligently to bring a different approach to hemostasis for gastroenterology teams across the United States.”

Hemospray will soon be available to clinicians across the U.S. for the treatment of non-variceal GI bleeds. This product is a single-use device that delivers hemostatic powder through the channel of an endoscope toward the source of a bleed. When the powder comes in contact with blood, it absorbs water and forms a gel, which acts cohesively and adhesively to create a stable mechanical barrier that covers the bleeding site. Hemospray is a nonthermal, nontraumatic treatment modality for achieving hemostasis.

“Hemospray gives clinicians another tool for the care of their patients,” said DJ Sirota, vice president of Cook Medical’s MedSurg division. “Patients have been our number one priority for over 50 years and we’ve worked hard to bring this innovation to the field of gastroenterology across the U.S.“

Numerous reports in the clinical literature have demonstrated the clinical utility of Hemospray when used alone or with other methods.2 In a summary of 19 studies of Hemospray comprising treatment of 234 patients, the combined rate of successful hemostasis was 88.5 percent. Rebleeding occurred within 72 hours in 16.2% after successful initial hemostasis with Hemospray.

Current endoscopic hemostasis treatment options can be challenging. Thermal, mechanical or contact devices can carry a risk of further tissue damage and require precise placement of the device directly onto the bleeding vessel.3 Hemospray represents a different approach to treat GI bleeds by helping to achieve hemostasis without the precision or direct visualization required of other current treatments.3 This makes Hemospray a treatment option for bleeding from damaged tissue where the bleeding source cannot be easily identified.


Reference

1 El-Tawil A., Trends on gastrointestinal bleeding and mortality: Where are we standing?, World J Gastroenterol, 2012. 18: 1154-58

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.